Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06545331
PHASE1

Study of XB010 in Subjects With Solid Tumors

Sponsor: Exelixis

View on ClinicalTrials.gov

Summary

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Official title: A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

396

Start Date

2024-08-06

Completion Date

2027-10-20

Last Updated

2026-06-22

Healthy Volunteers

No

Interventions

DRUG

XB010

IV administration of XB010

DRUG

Pembrolizumab

IV administration of Pembrolizumab

Locations (20)

City of Hope Orange County Lennar Foundation Cancer Center

Irvine, California, United States

UCLA Department of Medicine - Hematology/Oncology

Los Angeles, California, United States

Georgetown University Medical Center

Washington D.C., District of Columbia, United States

Sarah Cannon Research Institute at Florida Cancer Specialists

Orlando, Florida, United States

Winship Cancer Institute

Atlanta, Georgia, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Siteman Cancer Center

St Louis, Missouri, United States

Montefiore Medical Center - Montefiore Medical Park

The Bronx, New York, United States

Carolina BioOncology Institute

Huntersville, North Carolina, United States

Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

SCRI Oncology Partners

Nashville, Tennessee, United States

NEXT Austin

Austin, Texas, United States

Baylor University Medical Center

Dallas, Texas, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Inova Schar Cancer

Fairfax, Virginia, United States

NEXT Virginia

Fairfax, Virginia, United States

University Hospitals of Leicester NHS Trust

Leicester, United Kingdom

Sarah Cannon Research Institute London

London, United Kingdom

University College London Hospitals NHS Foundation Trust

London, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom